Background
Jade Teakell
FLOZINATing to the Future- Long Term Effects of ...

This week, we will discuss post-trial follow-up for EMPA-Kidney. What are the longer-term effects of empagliflozin for patients with chronic kidney disease?

FLOZINATing to the Future- Long Term Effects of Empagliflozin in Patients with CKD
Background
Brian Rifkin
The Ondansetron Ballet: Torsades de Pointes

Nausea is a very common and distressing problem. Some medications that treat nausea carry a higher risk for arrhythmias, like Torsades de Pointes, and sudden cardiac death. Is ondansetron safe for use in patients on hemodialysis?

The Ondansetron Ballet: Torsades de Pointes
Background
Cristina Adriana Popa
Re”FINE”ing the role of non steroidal MRAs in ...

This week, we will discuss non-steroidal mineralocorticoid antagonist in the multiverse of cardiovascular-kidney-metabolic. What FINEHEART pooled analysis would add to what we already learned from FIDELIO-DKD trial?

Re”FINE”ing the role of non steroidal MRAs in Cardio Kidney Metabolic syndrome
Background
Cristina Adriana Popa
Playing It Safe: Can Felzartamab Fill the Gap ...

This week is time antibody mediated rejection treatment in kidney transplant. A new molecule targeting CD38, on the horizon, safely tested in a phase 2 trial

Playing It Safe: Can Felzartamab Fill the Gap in AMR Treatment?
Background
Jade Teakell
The pressure is on! Unravelling the ESPRIT of ...

This week, we will discuss the ongoing saga of blood pressure targets in patients with hypertension. This time its ESPRIT (Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing Risk of Vascular Events) making a case for case for intensive BP control in most hypertensive individuals, including those with a history of diabetes and stroke.

The pressure is on! Unravelling the ESPRIT of Intensive vs Standard BP Control

finerenone

Análisis del Estudio FINE-HEART_El Resumen Visual

El análisis FINE-HEART llega a NephJC, donde se agrupan tres ensayos clínicos clave que evalúan el impacto de la finerenona en pacientes con insuficiencia cardíaca y enfermedad renal diabética.

¿Será la finerenona la próxima terapia de impacto para mejorar el eje cardio-reno-metabólico?

Descubre más en este resumen visual creado por la estudiante del NSMC, @KajareeG

Re”FINE”ing the role of non steroidal MRAs in Cardio Kidney Metabolic syndrome

Re”FINE”ing the role of non steroidal MRAs in Cardio Kidney Metabolic syndrome

This week, we will discuss non-steroidal mineralocorticoid antagonist in the multiverse of cardiovascular-kidney-metabolic. What FINEHEART pooled analysis would add to what we already learned from FIDELIO-DKD trial?